イリノイ州における乳がんの臨床試験
イリノイ州内の拠点で、乳がんに関する81件の研究が参加者を募集しています。
イリノイ州内の都市
- Chicago58件の研究
- Evanston13件の研究
- Waukegan12件の研究
- Champaign11件の研究
- Cicero11件の研究
- Naperville9件の研究
- Decatur8件の研究
- Springfield8件の研究
- Peoria8件の研究
- Aurora7件の研究
- Arlington Heights7件の研究
- Carbondale6件の研究
- Bloomington5件の研究
- Danville5件の研究
- Rockford5件の研究
- Galesburg5件の研究
- Charleston5件の研究
- North Peoria5件の研究
- Joliet4件の研究
- Elgin4件の研究
公式研究テキスト（英語）
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Affiliated Oncologists IL, Chicago
- Hope And Healing Care, Hinsdale
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- 他54件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- University of Illinois Cancer Center, Chicago
- The University of Chicago, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06369285Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Orchard Healthcare Research Inc.- Skokie, Skokie
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05868226Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Northwestern Medicine Chicago Proton Center, Warrenville
被験者募集中第2相
50歳以上 · 女性 · 2026/09/29更新 · NCT01766297Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/09/28更新 · NCT07553234A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Rush University Medical Center ( Site 0079), Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- City of Hope Chicago, Zion
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Peoria
- Clinical Trial Site, Urbana
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Northwestern University, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/09/23更新 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Chicago, Chicago
被験者募集中健康なボランティア歓迎
30歳〜74歳 · 女性 · 2026/09/21更新 · NCT02620852ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Cancer Care Specialists, Decatur
- Cancer Care Specialists of Illinois, O'Fallon
- Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University of Illinois Hospital & Health Sciences System, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06827236A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Illinois Cancer Specialists, Arlington Heights
- Northwestern Memorial Hospital, Chicago
- RUSH MD Anderson Cancer Center, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
- Orchard Healthcare Research Inc., Skokie
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/11更新 · NCT05935384A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT03424005Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Orchard Healthcare Research Inc. ( Site 0006), Skokie
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Chicago, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Carle Cancer Center, Urbana
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05386108A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- NorthShore University Health System - Evanston Hospital, Evanston
- NorthShore University HealthSystem - Evanston Hospital, Evanston
- Duly Health and Care, Lisle
- 他2件
被験者募集中第1相
18歳〜55歳 · 女性 · 2026/09/09更新 · NCT07310420A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Evanston
被験者募集中第3相
18歳〜130歳 · 全性別 · 2026/09/08更新 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- City of Hope® Cancer Center Chicago, Zion
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07100106Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Northwestern University, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT05315700Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
- Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06062498Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Rush University Medical Center, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Southern Illinois Hospital Services, Carbondale
- Cancer Care Specialist of Illinois, O'Fallon
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- University of Illinois Cancer Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT04886531A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Cancer Care Specialists of Central Illinois, O'Fallon
- Springfield Clinic, Springfield
- Carle Cancer Center, Urbana
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- 他83件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Northwestern University, Chicago
- Southern Illinois University-Simmons, Springfield
- Carle Foundation Cancer Institute-Urbana, Urbana
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
被験者募集中健康なボランティア歓迎
25歳以上 · 女性 · 2026/09/01更新 · NCT03729115TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Chicago Medical Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/26更新 · NCT06533826A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06764940BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- University of Illinois, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06441890ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。